一项涉及 1,151 名糖尿病患者的研究显示，降胆固醇药物非诺贝特可使糖尿病视网膜病变进展减缓 27%。 Fenofibrate, a cholesterol-lowering drug, showed a 27% reduction in diabetic retinopathy progression in a study involving 1,151 diabetes patients.
研究发现，降胆固醇药物非诺贝特可以潜在地减缓糖尿病视网膜病变的进展，而糖尿病视网膜病变是糖尿病患者视力丧失的常见原因。 A cholesterol-lowering drug, fenofibrate, has been found to potentially slow the progression of diabetic retinopathy, a common cause of vision loss in people with diabetes. 牛津人口健康 LENS 试验开展的一项研究涉及 1,151 名患有 1 型或 2 型糖尿病的患者，对非诺贝特与安慰剂进行了比较。 A study conducted by Oxford Population Health's LENS trial involved 1,151 participants with type 1 or type 2 diabetes, comparing fenofibrate to a placebo. 研究结果显示，与服用安慰剂的受试者相比，服用非诺贝特的受试者眼部疾病进展减少了 27%，这表明该药物可能成为治疗糖尿病视网膜病变患者的有益补充。 The results showed a 27% reduction in eye disease progression among participants taking fenofibrate compared to those on placebo, suggesting that the drug could be a valuable addition for treating people with diabetic retinopathy.